3 . 24 . 2026Press releaseAAD 2026: Galderma showcases latest evidence supporting its full-spectrum, science-driven solutions for diverse skin needs
From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of...
Publisher
Switzerland
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of...
Source route
Continue on galderma.com
Leave the platform to read the original full article on the publisher site.
Source: Galderma
Scope: Industry
Related coverage
More related coverage
Mar.26.2026R & DOno Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan
Application submitted for manufacturing and marketing approval of ripretinib in Japan for the indica...
March 25, 2026
Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhib...